Coloplast A/S

COLO B

Equity

ISIN DK0060448595 / Valor 20259063

Nasdaq Copenhagen Equities (2024-11-20)

DKK 881.00-1.37%

Coloplast A/S
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Coloplast A/S is a global company with approximately 14,500 employees that specializes in developing products and services for individuals with Ostomy Care, Continence Care, Wound & Skin Care, Interventional Urology, and Voice & Respiratory Care needs. The company focuses on providing innovative solutions to improve the quality of life for those with personal and private medical conditions.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Coloplast A/S reported an 8% organic growth in Q2 of the financial year 2023/24, with a reported revenue increase of 9% in DKK. This growth was driven by strong performances across various business areas, including Ostomy Care, Continence Care, Voice and Respiratory Care, and Advanced Wound Care.

EBIT Margin

The EBIT margin for Coloplast A/S in Q2 2023/24 was 27%, slightly down from 28% in the previous year. This includes a negative impact of around 100 basis points from the acquisition of Kerecis and currency fluctuations.

Dividends

Coloplast A/S announced a half-year interim dividend of DKK 5.00 per share, resulting in a total dividend payout of DKK 1,125 million. This reflects the company's commitment to returning value to its shareholders.

Free Cash Flow

Free cash flow for Coloplast A/S in H1 2023/24 was an outflow of DKK 1.3 billion, primarily due to an extraordinary tax payment related to Atos Medical’s Intellectual Property transfer. Adjusted for this tax payment, the free cash flow was an inflow of DKK 1.2 billion.

Outlook

Coloplast A/S maintained its guidance for FY 2023/24, expecting organic revenue growth of around 8% and a reported EBIT margin before special items of 27-28%. The company also adjusted its reported revenue growth forecast to 10-11%, considering the negative impact of currency fluctuations.

Summarized from source with an LLMView Source

Key figures

17.1%1Y

-25.0%3Y

9.20%5Y

Performance

25.6%1Y

27.9%3Y

27.2%5Y

Volatility